April 27, 2018 / 11:22 AM / in a month

BRIEF-AcelRx Receives Positive CHMP Opinion For Dzuveo For Management Of Acute Moderate To Severe Pain In Medically Monitored Settings

April 27 (Reuters) - AcelRx Pharmaceuticals Inc:

* ACELRX RECEIVES POSITIVE CHMP OPINION FOR DZUVEO™ FOR MANAGEMENT OF ACUTE MODERATE TO SEVERE PAIN IN MEDICALLY MONITORED SETTINGS

* ACELRX PHARMACEUTICALS INC - RESUBMISSION OF NEW DRUG APPLICATION FOR DSUVIA (KNOWN AS DZUVEO IN EUROPE) TO FDA IN U.S. IS PLANNED FOR Q2 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below